Trial Profile

A Phase 2 Study of LY2090314 in Participants With Acute Leukemia.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Nov 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LY 2090314 (Primary)
Indications Acute myeloid leukaemia; Acute promyelocytic leukaemia
Focus Adverse reactions
Sponsors Eli Lilly and Company

Most Recent Events

01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
21 Feb 2012 Planned number of patients changed from 26 to 38 as reported by M.D. Anderson Cancer Center.
21 Feb 2012 New source identified and integrated (2011-0838; M.D. Anderson Cancer Center).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com